DALLAS, TX / ACCESSWIRE / July 8, 2020 / Mateon Therapeutics (OTCQB:MATN)
The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/MATN%20Initiation%20-2.pdf
COMPANY DESCRIPTION
Mateon Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing drugs for the treatment of orphan oncology indications with a specialization in rare pediatric cancers. The Company is a developer of antisense therapeutic called "OT-101" fighting TGF-beta as a immunotherapy for a broad range of cancers. Mateon has completed phase 2 trials for pancreatic cancer and melanoma as well as glioblastoma. The Company is pursuing a phase 3 trial in China through a proposed joint venture with a Chinese company for pancreatic cancer to start in Q3 2020. Mateon is also seeking to treat COVID-19 with their OT-101 candidate. The Phase 2 COVID-19 trial will be managed by IQVIA. The Company has a total of six primary programs they will seek to advance including using. Mateon was formed through a reverse merger of Oncotelic Inc. into Mateon in April 2019 followed by the acquisition of PointR Data Inc. in November 2019. The Company's corporate office is located in Agoura Hills, CA.
SUMMARY
• Mateon's lead candidate Trabedersen (OT-101) is designed to specifically target the human TGF-beta messenger RNA, which suppresses host innate immune response to cancers. OT-101 treatment is designed to lift the cloaking effect on cancer cells and allows innate or therapeutic immunity to attack and eliminate the cancers.
• OT-101 has already completed phase 2 for pancreatic cancer and melanoma and phase 2 in glioblastoma with robust efficacy and safety noted. The Company is expecting to enter into a phase 3 trial in China after a proposed joint venture (JV) with a Chinese company to start in Q3 2020.
• The Company is also planning to conduct a 30 patient pivotal trial in the United States in Q4 2020 focusing on pediatric diffuse intrinsic pontine glioma (DIPG), the second most common pediatric brain tumor, where the current standard of care treatment has an average overall survival rate of less than 1 year.
• MATN is also using their OT-101 candidate to combat COVID-19 in a proposed randomized, double-blind, placebo-controlled trial in adult patients hospitalized with SARS-CoV-2 and pneumonia in the U.S. The Company is seeking to suppress replication of SARS-CoV-2 by suppressing TGF-beta messenger RNA. Initial data has shown successful suppression of SAR-CoV2 replication with efficacy and safety on par with Gilead's drug Remdesivir with the added benefit of targeting the virus induced pneumonia and fibrosis.
• Mateon has two additional pipeline drugs called CA4P and Oxi4503 which are vascular disruptor agents with extensive phase 1/2 testing that are ready to move into pivotal clinical trials. CA4P is used in combination with Ipilimumab for the treatment of solid tumors with a focus on melanoma, while Oxi4503 is used for the treatment of liquid tumors with a focus on childhood leukemia.
• In November 2019, Mateon acquired PointR Data Inc., an artificial intelligence (AI) company in order to enhance their ability to gather real world evidence for clinical trials and drug manufacturing. The Company develops and deploys high performance cluster computers to create an interconnected grid harvesting operational data within manufacturing plants, hospitals, and clinics. This has the potential to improve manufacturing operations and data reliability and security. In addition to using PointR's AI for drug discovery, the technology is also being used for contact tracing which will monitor the spread of COVID-19.
• PointR's technology has the added benefit of being partnered with IBM in multiple areas including sales and marketing. This partnership between Mateon and IBM should help the Company in penetrating larger pharma manufacturers and provide additional services to smaller, regional manufacturers.
• With promising clinical data and several programs in the pipeline addressing sizable markets with unmet needs, our comparables analysis shows that MATN remains undervalued at current levels. See page 8 for further details.
About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.
CONTACT:
Stonegate Capital Partners
Shane Martin, CFA
(214) 987-4121
shane@stonegateinc.com
SOURCE: Stonegate Capital Partners
View source version on accesswire.com:
https://www.accesswire.com/596629/Stonegate-Capital-Partners-Initiates-Coverage-on-Mateon-Therapeutics-OTCMATN